Abstract
Kidney and liver are the main organs involved in the elimination of drugs. In general, the elimination capacity of the kidney is lower than of the liver, because of the smaller organ size and associated blood flow. Renal excretion can be limited by glomerular filtration rate in case of passive excretion or transporter capacity by total renal blood flow and in case of active secretion. Impaired renal function is a rather common condition in patients. Therefore, both dedicated studies in patients with renal impairment and pharmacokinetic investigations via means of population pharmacokinetics are routinely used in drug development to investigate if a dose adjustment needs to be applied in this vulnerable population.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References and Further Reading
Bruno R, Baille P, Retout S, Vivier N, Veyrat-Follet C, Sanderink GJ, Becker R, Antman EM (2003) Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 56:407–414
Centers for Disease Control and Prevention (2018) Chronic kidney disease surveillance system website. http://www.cdc.gov/ckd. Accessed 6 Dec 2018
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
EMA/CHMP/83874/2014 (2015) Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. https://www.ema.europa.eu/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf
Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX (2002) Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 105:225–231
US FDA (2007) Lovenox® (enoxaparin sodium injection) for subcutaneous and intravenous use; highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022138,020164s075lbl.pdf
US FDA (2010) Guidance for industry: pharmacokinetics in patients with impaired renal function – study design, data analysis, and impact on dosing and labelling. March 2010, revision 1. https://www.fda.gov/downloads/drugs/guidances/ucm204959.pdf
US National Kidney Foundation (2012) KDIGO clinical practice guideline for the evaluation and management of CKD. https://www.kidney.org/content/mdrd-study-equation
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Sanderink, G., Kovar, A. (2020). Special Populations: Renal Impairment. In: Hock, F., Gralinski, M. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-68864-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-68864-0_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68863-3
Online ISBN: 978-3-319-68864-0
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences